Better play than HIMS due to pharmacy ownership; high upside tied to the July 23rd FDA meeting regarding compound peptides.

The market trend of patients switching from expensive GLP-1s to affordable oral medications is seen as a positive indicator for the company as it offers similar diversified weight loss programs.

Cited as an 'under-followed, unknown hyper-growth stock' that is less correlated to the broader market, offering portfolio protection during crashes. It was down only 3% in a recent sell-off.

Used as an example to highlight the cash flow problems of dealing with insurance; the company ships products but may not get paid if insurance denies a claim, forcing it to absorb the loss.

A deep-value play in digital health, considered 'way too cheap' and valued at about four times cheaper than its competitor HIMS. The investment thesis is based on its low valuation being too cheap to ignore, despite slower execution.

The speaker is bearish on LifeMD when compared to HIMS, criticizing its strategy of working within the traditional insurance system, which is believed to make it less agile and slower to innovate.

Mentioned as an example of a '#2 player' or 'challenger' stock to Hims & Hers within the investment theme of backing challengers.

Highlighted as an example of a small-cap stock that has been pushed down too far in an indiscriminate market sell-off and is now considered 'too cheap'.

Presented as a significantly undervalued value play compared to its peer HIMS, being 'three times cheaper' on a price-to-growth basis. The company is cash flow positive, has no debt, high gross margins, and a key differentiator in its strategy of working with insurance for branded GLP-1s.

The stock has seen a massive 70% drawdown and is considered 'unprecedentedly cheap' with a valuation metric of 0.029, presenting a deep value opportunity for investors who believe in its subscription model.